| __timestamp | Blueprint Medicines Corporation | Catalyst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 4473654 |
| Thursday, January 1, 2015 | 14456000 | 8597010 |
| Friday, January 1, 2016 | 19218000 | 7910260 |
| Sunday, January 1, 2017 | 27986000 | 7304399 |
| Monday, January 1, 2018 | 47928000 | 15875961 |
| Tuesday, January 1, 2019 | 96388000 | 36881187 |
| Wednesday, January 1, 2020 | 157743000 | 44233754 |
| Friday, January 1, 2021 | 195293000 | 49628000 |
| Saturday, January 1, 2022 | 237374000 | 58183000 |
| Sunday, January 1, 2023 | 295141000 | 133710000 |
| Monday, January 1, 2024 | 359272000 |
Igniting the spark of knowledge
In the competitive landscape of pharmaceuticals, understanding spending patterns is crucial. Over the past decade, Blueprint Medicines Corporation and Catalyst Pharmaceuticals, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Blueprint Medicines saw a staggering increase of over 3,600% in SG&A expenses, peaking at nearly $295 million in 2023. In contrast, Catalyst Pharmaceuticals experienced a more modest rise of approximately 2,900%, reaching $134 million in the same year.
This divergence highlights Blueprint's aggressive expansion strategy, possibly reflecting increased marketing efforts and administrative scaling. Meanwhile, Catalyst's steadier growth suggests a more conservative approach. These spending patterns not only reflect each company's strategic priorities but also offer insights into their market positioning and future growth potential.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Catalyst Pharmaceuticals, Inc.
Pfizer Inc. and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Viatris Inc. and Blueprint Medicines Corporation
Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Catalyst Pharmaceuticals, Inc.
Insmed Incorporated and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Dr. Reddy's Laboratories Limited vs Catalyst Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Madrigal Pharmaceuticals, Inc.
Blueprint Medicines Corporation and MorphoSys AG: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Galapagos NV
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Xencor, Inc.
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Catalyst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Vericel Corporation and Catalyst Pharmaceuticals, Inc.